EQS-News: SYNBIOTIC welcomes Green Party’s proposal for the Industrial Hemp Liberalization Act and calls for objectivity in the medical cannabis debate

SYNBIOTIC welcomes Green Party’s proposal for the Industrial Hemp Liberalization Act and calls for objectivity in the medical cannabis debate

The European medical cannabis and industrial hemp group SYNBIOTIC SE (ISIN DE000A3E5A59 | WKN A3E5A5) considers the bill introduced by Bündnis 90/Die Grünen on 7 October 2025 to amend the Consumer Cannabis Act (KCanG) an important step towards greater legal certainty, innovation, and competitiveness for the German hemp industry. At the same time, the company is closely monitoring the planned tightening of the Medical Cannabis Act (MedCanG).

Momentum for the hemp industry: liberalization of industrial hemp opens new perspectives

The Greens’ proposal aims to remove the so-called “intoxication clause”, raise the THC limit for industrial hemp from 0.3% to 1%, and permit indoor cultivation. This would align Germany with practices already established in other EU countries such as the Czech Republic. The reform would significantly expand the economic scope for cultivation, processing, and product development within the industrial hemp sector.

According to SYNBIOTIC, the proposed liberalization would represent an important impulse for sustainable agriculture, innovation, and regional value creation. The Group is well integrated across Europe and strongly positioned in the industrial hemp market through subsidiaries such as Hempro International, Hemp Factory, and Ilesol, and therefore sees significant potential to further develop hemp as a sustainable raw material for future industries.

Daniel Kruse, CEO of SYNBIOTIC: “For decades, we have been advocating for evidence-based and innovation-driven hemp policies. The Greens’ initiative is a signal of progress and reinforces confidence in the future of industrial hemp. As President of the European Industrial Hemp Association (EIHA), entrepreneur of 30 years, and CEO of SYNBIOTIC, I hope that Federal Agriculture Minister Alois Rainer will recognize the enormous potential of this crop for agriculture, industry, and trade.”

Criticism of the MedCanG reform: patient care must not suffer

The draft bill presented by Federal Health Minister Nina Warken (CDU) to amend the Medical Cannabis Act has sparked broad criticism. It includes a ban on mail-order sales and stricter rules for online prescriptions. Industry associations, patient initiatives, and companies warn of significant risks.

• 86% of respondents in a recent survey expect the changes to worsen patient access and strengthen the black market.
• The SPD parliamentary group announced that it would not support the bill in its current form, calling it “overregulated” and “hostile to patients.”
• Industry leaders, including the CEOs of Bloomwell, Sanity Group, and Demecan, criticized the proposed ban on mail-order sales as a “setback for patient care and digitalization.”
• The Federal Association of German Mail-Order Pharmacies (BVDVA) rejected the plans as “not in the interest of patients,” describing them as “unjustified restrictions on reputable providers.”

SYNBIOTIC SE calls for objective and differentiated regulation. A functioning medical cannabis market requires reliability, quality standards, and digital healthcare solutions—not sweeping restrictions that stifle progress. At the same time, the company emphasizes that unregulated telemedicine platforms must not be allowed to create parallel systems outside of existing healthcare structures.

Daniel Kruse, CEO of SYNBIOTIC, adds: “Patient access, product safety, and medical quality must not be played off against each other. Modern healthcare requires trust in doctors and pharmacies—both in-person and online—alongside regulated suppliers and clear standards, but not blunt prohibitions.”

SYNBIOTIC: dual strategy combining innovation and responsibility

With its engagement in both medical cannabis and industrial hemp, SYNBIOTIC positions itself as an investment platform for two billion-euro markets that share similar needs and vast potential. Both sectors offer significant opportunities for sustainable value creation—provided that stable, modern, and science-based regulatory frameworks are established.

SYNBIOTIC will continue to actively participate in political and regulatory processes to promote practical and forward-looking solutions for patients, customers, farmers, industry, and investors alike.

Publisher
SYNBIOTIC SE
Daniel Kruse
CEO
Münsterstrasse 336
40470 Düsseldorf
Germany
www.synbiotic.com

Media
Rüdiger Tillmann
SYNBIOTIC Public Relations Manager
Email ruediger.tillmann@synbiotic.com
Mobile +49 171 3677028
c/o JOLE.group

About SYNBIOTIC
SYNBIOTIC is a listed group of companies in the medical cannabis and industrial hemp sector with a buy-and-build investment strategy focussed on Europe. The Group covers the entire value chain from cultivation to production and retail - from the field to shelf. The subsidiaries' core businesses are research and development, production and the commercialisation of medical cannabis, industrial hemp and CBD products.
SYNBIOTIC is pursuing a clear pan-European strategy of further expanding its business areas in order to cover the relevant growth markets while minimising risks and increasing opportunities for investors through diversification.